Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321436260> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4321436260 endingPage "1910" @default.
- W4321436260 startingPage "1903" @default.
- W4321436260 abstract "Abstract Background Safer, better, and shorter treatments for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are an urgent global health need. The phase 3 clinical trial Nix-TB (NCT02333799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bedaquiline, and pretomanid (BPaL). In this study, we investigate the relationship between the pharmacokinetic characteristics of the drugs, patient characteristics and efficacy endpoints from Nix-TB. Methods Pharmacokinetic data were collected at weeks 2, 8, and 16. Efficacy endpoints including treatment outcomes, time to stable culture conversion, and longitudinal time to positivity in the mycobacterial growth indicator tube assay were each characterized using nonlinear mixed-effects modeling. Relationships between patient, treatment pharmacokinetics, and disease characteristics and efficacy endpoints were evaluated. Results Data from 93 (85% of the total) participants were analyzed. Higher body mass index was associated with a lower incidence of unfavorable treatment outcomes. Median time to stable culture conversion was 3 months in patients with lower baseline burden compared with 4.5 months in patients with high baseline burden. Participants with minimal disease had steeper time to positivity trajectories compared with participants with high-risk phenotypes. No relationship between any drugs’ pharmacokinetics (drug concentration or exposure metrics) and any efficacy outcomes was observed. Conclusions We have successfully described efficacy endpoints of a BPaL regimen from the Nix-TB trial. Participants with high-risk phenotypes significantly delayed time to culture conversion and bacterial clearance. The lack of a relationship between pharmacokinetic exposures and pharmacodynamic biomarkers opens the possibility to use lower, safer doses, particularly for toxicity-prone linezolid. Clinical Trials Registration NCT02333799." @default.
- W4321436260 created "2023-02-22" @default.
- W4321436260 creator A5018160968 @default.
- W4321436260 creator A5031278604 @default.
- W4321436260 creator A5033026230 @default.
- W4321436260 creator A5090053095 @default.
- W4321436260 date "2023-02-21" @default.
- W4321436260 modified "2023-10-14" @default.
- W4321436260 title "Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial" @default.
- W4321436260 cites W105671925 @default.
- W4321436260 cites W1555920164 @default.
- W4321436260 cites W2038014660 @default.
- W4321436260 cites W2039192863 @default.
- W4321436260 cites W2114110528 @default.
- W4321436260 cites W2116131202 @default.
- W4321436260 cites W2136461272 @default.
- W4321436260 cites W2495427592 @default.
- W4321436260 cites W2516905116 @default.
- W4321436260 cites W2531669844 @default.
- W4321436260 cites W2889510886 @default.
- W4321436260 cites W2895784427 @default.
- W4321436260 cites W2909813694 @default.
- W4321436260 cites W2965504792 @default.
- W4321436260 cites W3009599329 @default.
- W4321436260 cites W3022045851 @default.
- W4321436260 cites W3092694347 @default.
- W4321436260 cites W3165446115 @default.
- W4321436260 cites W3180126454 @default.
- W4321436260 cites W3191249477 @default.
- W4321436260 cites W3203339101 @default.
- W4321436260 cites W4293842430 @default.
- W4321436260 doi "https://doi.org/10.1093/cid/ciad051" @default.
- W4321436260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36804834" @default.
- W4321436260 hasPublicationYear "2023" @default.
- W4321436260 type Work @default.
- W4321436260 citedByCount "3" @default.
- W4321436260 countsByYear W43214362602023 @default.
- W4321436260 crossrefType "journal-article" @default.
- W4321436260 hasAuthorship W4321436260A5018160968 @default.
- W4321436260 hasAuthorship W4321436260A5031278604 @default.
- W4321436260 hasAuthorship W4321436260A5033026230 @default.
- W4321436260 hasAuthorship W4321436260A5090053095 @default.
- W4321436260 hasBestOaLocation W43214362601 @default.
- W4321436260 hasConcept C111113717 @default.
- W4321436260 hasConcept C112705442 @default.
- W4321436260 hasConcept C126322002 @default.
- W4321436260 hasConcept C142724271 @default.
- W4321436260 hasConcept C203092338 @default.
- W4321436260 hasConcept C2776301714 @default.
- W4321436260 hasConcept C2777768864 @default.
- W4321436260 hasConcept C2777975735 @default.
- W4321436260 hasConcept C2780544761 @default.
- W4321436260 hasConcept C2781069245 @default.
- W4321436260 hasConcept C2781413609 @default.
- W4321436260 hasConcept C535046627 @default.
- W4321436260 hasConcept C71924100 @default.
- W4321436260 hasConcept C98274493 @default.
- W4321436260 hasConceptScore W4321436260C111113717 @default.
- W4321436260 hasConceptScore W4321436260C112705442 @default.
- W4321436260 hasConceptScore W4321436260C126322002 @default.
- W4321436260 hasConceptScore W4321436260C142724271 @default.
- W4321436260 hasConceptScore W4321436260C203092338 @default.
- W4321436260 hasConceptScore W4321436260C2776301714 @default.
- W4321436260 hasConceptScore W4321436260C2777768864 @default.
- W4321436260 hasConceptScore W4321436260C2777975735 @default.
- W4321436260 hasConceptScore W4321436260C2780544761 @default.
- W4321436260 hasConceptScore W4321436260C2781069245 @default.
- W4321436260 hasConceptScore W4321436260C2781413609 @default.
- W4321436260 hasConceptScore W4321436260C535046627 @default.
- W4321436260 hasConceptScore W4321436260C71924100 @default.
- W4321436260 hasConceptScore W4321436260C98274493 @default.
- W4321436260 hasIssue "11" @default.
- W4321436260 hasLocation W43214362601 @default.
- W4321436260 hasLocation W43214362602 @default.
- W4321436260 hasLocation W43214362603 @default.
- W4321436260 hasOpenAccess W4321436260 @default.
- W4321436260 hasPrimaryLocation W43214362601 @default.
- W4321436260 hasRelatedWork W2227061539 @default.
- W4321436260 hasRelatedWork W2262666571 @default.
- W4321436260 hasRelatedWork W2807439384 @default.
- W4321436260 hasRelatedWork W2916256405 @default.
- W4321436260 hasRelatedWork W2922915119 @default.
- W4321436260 hasRelatedWork W2980679879 @default.
- W4321436260 hasRelatedWork W2992709639 @default.
- W4321436260 hasRelatedWork W3142115330 @default.
- W4321436260 hasRelatedWork W3166151627 @default.
- W4321436260 hasRelatedWork W4385629095 @default.
- W4321436260 hasVolume "76" @default.
- W4321436260 isParatext "false" @default.
- W4321436260 isRetracted "false" @default.
- W4321436260 workType "article" @default.